TCM
ACAD icon

TimesSquare Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

TimesSquare Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-383,200
Closed -$12.2M – 242
2016
Q3 		$12.2M Buy
383,200
+54,400
+17% +$1.84M 0.08% 220
2016
Q2 		$10.7M Buy
+328,800
New +$11M 0.07% 213

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

TimesSquare Capital Management's ACAD Position: Q4 2016 in Review

TimesSquare Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 383,200 shares — an estimated $12.2M sold.

TimesSquare Capital Management first reported a position in ACAD in Q2 2016 and held it in 2 quarters. The position peaked at $12.2M in Q3 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • TimesSquare Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • TimesSquare Capital Management sold 383,200 Acadia Pharmaceuticals shares in Q4 2016, an estimated $12.2M.
  • TimesSquare Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • TimesSquare Capital Management's Acadia Pharmaceuticals position peaked at $12.2M in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on TimesSquare Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.